Liver Cancer
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 21, 2006; 12(31): 4966-4972
Published online Aug 21, 2006. doi: 10.3748/wjg.v12.i31.4966
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Alterations of hepatic telomerase at different stages of rat hepatoma model. The feed of experimental rats contained 0.05% of 2-fluoenylacetamide. Exp-1: Hepatocyte degeneration group; Exp-2: Hepatocyte precancerosis group; Exp-3: Hepatocyte cancerization group; and Con, rats given basal feed without 2-fluoenylacetamide as normal control group.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Alterations of liver total RNA at different stages of rat hepatoma model. The feed of experimental rats contained 0.05% of 2-fluoenylacetamide. Exp-1: Hepatocyte degeneration group; Exp-2: Hepatocyte precancerosis group; Exp-3: Hepatocyte cancerization group; and Con, rats given basal feed without 2-fluoenylacetamide as normal control group.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Comparative analysis of total RNA levels and telomerase activities in human hepatoma tissues and their non-cancerous tissues.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Electrophoresis patterns of human telomerase in polya-crylamide gel. A,C: Human hepatocellular carcinoma tissues; B,D: Non-cancerous tissues of human hepatocellular carcinoma; E: Negative control.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Comparative analyses of telomerase activities in peripheral blood mononuclear cells from patients with benign or malignant liver diseases.